We are live on ! Find out more
LIMNW

Liminatus Pharma Warrants
LIMNW

Fund managers haven’t disclosed any holdings of LIMNW yet.

LIMNW Hedge Fund Activity: Q1 2026 in Review

21 of the 8,143 institutional investors tracked by Wall St. Rank reported a position in Liminatus Pharma Warrants (LIMNW) for Q1 2026, worth a combined $72.6K — down 24% from $95K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of LIMNW and 0 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 1 added.

The largest buyer was UBS Group, adding an estimated $19. The largest seller was Clear Street, cutting an estimated $51.5K.

  • 21 institutional investors held Liminatus Pharma Warrants (LIMNW) as of Q1 2026, down from 24 in Q4 2025.
  • Funds reported $72.6K of Liminatus Pharma Warrants stock for Q1 2026, down 24% quarter-over-quarter.
  • 0 funds opened new Liminatus Pharma Warrants positions in Q1 2026 and 3 closed out, a net change of -3 holders.
  • The largest Liminatus Pharma Warrants buyer in Q1 2026 was UBS Group, an estimated $19 added.
  • The largest Liminatus Pharma Warrants seller in Q1 2026 was Clear Street, an estimated $51.5K sold.

Based on aggregated 13F filings for Q1 2026.